Recipharm AB publishes its report for the fourth quarter and full year 2018
October – December 2018 · Net sales amounted to SEK 1,739 million (1,403), an increase of 24% · EBITDA1/increased by 24% to SEK 280 million (226) corresponding to an EBITDA1/margin of 16.1% (16.1) · Operating profit (EBIT) amounted to SEK -2 million (-160) · Profit after tax amounted to SEK -41 million (-183) corresponding to a net margin of -2.3% (-13.0) · Earnings per share amounted to SEK -0.59 (-2.96) before dilution and SEK -0.59 (-2.96) after dilution. Adjusted for non-recurring items earnings per share amounted to SEK 1.07 (0.83) · Recipharm announced the